Schultheiss JPD - Search Results

1

Mahmoud R, Schultheiss JPD, Fidder HH, Oldenburg B. Mahmoud R, et al. Among authors: schultheiss jpd. Clin Gastroenterol Hepatol. 2023 Feb;21(2):558-559. doi: 10.1016/j.cgh.2022.04.004. Epub 2022 Apr 26. Clin Gastroenterol Hepatol. 2023. PMID: 35483605 No abstract available.

2

Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases - the longer the less? Authors' reply.

Schultheiss JPD, Mahmoud R, Fidder HH, Oldenburg B. Schultheiss JPD, et al. Aliment Pharmacol Ther. 2022 Jan;55(2):246. doi: 10.1111/apt.16722. Aliment Pharmacol Ther. 2022. PMID: 34970765 No abstract available.

3

Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.

Mahmoud R, Schultheiss JPD, Fidder HH, Oldenburg B. Mahmoud R, et al. Among authors: schultheiss jpd. Aliment Pharmacol Ther. 2022 Feb;55(4):499-500. doi: 10.1111/apt.16757. Aliment Pharmacol Ther. 2022. PMID: 35092052 No abstract available.

4

Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review.

van de Meeberg MM, Schultheiss JPD, Oldenburg B, Fidder HH, Huitema ADR. van de Meeberg MM, et al. Among authors: schultheiss jpd. Digestion. 2020;101(3):245-261. doi: 10.1159/000499331. Epub 2019 Apr 23. Digestion. 2020. PMID: 31013494 Free article.

5

Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.

Schultheiss JPD, Brand EC, Lamers E, van den Berg WCM, van Schaik FDM, Oldenburg B, Fidder HH. Schultheiss JPD, et al. Aliment Pharmacol Ther. 2019 Aug;50(4):386-396. doi: 10.1111/apt.15380. Epub 2019 Jul 16. Aliment Pharmacol Ther. 2019. PMID: 31310690

6

Adherence to Adalimumab Was Not Improved by a Reminder-Based Intervention with an Electronic Needle Container.

Schultheiss JPD, Altena S, Clevers MR, Baas D, Jharap B, Fidder HH. Schultheiss JPD, et al. Dig Dis Sci. 2021 May;66(5):1477-1487. doi: 10.1007/s10620-020-06395-z. Epub 2020 Jun 16. Dig Dis Sci. 2021. PMID: 32556818 Free PMC article.

7

Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.

Mahmmod S, Schultheiss JPD, van Bodegraven AA, Dijkstra G, Gilissen LPL, Hoentjen F, Lutgens MWMD, Mahmmod N, van der Meulen-de Jong AE, Smits LJT, Tan ACITL, Oldenburg B, Fidder HH. Mahmmod S, et al. Among authors: schultheiss jpd. Inflamm Bowel Dis. 2021 Nov 15;27(12):1954-1962. doi: 10.1093/ibd/izaa364. Inflamm Bowel Dis. 2021. PMID: 33538298

8

Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease.

Schultheiss JPD, Mahmoud R, Louwers JM, van der Kaaij MT, van Hellemondt BP, van Boeckel PG, Mahmmod N, Jharap B, Fidder HH, Oldenburg B. Schultheiss JPD, et al. Aliment Pharmacol Ther. 2021 Nov;54(10):1298-1308. doi: 10.1111/apt.16605. Epub 2021 Sep 24. Aliment Pharmacol Ther. 2021. PMID: 34559428 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page